John Fry

4.5k total citations · 2 hit papers
48 papers, 3.1k citations indexed

About

John Fry is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, John Fry has authored 48 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Epidemiology, 28 papers in Hepatology and 11 papers in Infectious Diseases. Recurrent topics in John Fry's work include Hepatitis B Virus Studies (29 papers), Hepatitis C virus research (27 papers) and Liver Disease Diagnosis and Treatment (16 papers). John Fry is often cited by papers focused on Hepatitis B Virus Studies (29 papers), Hepatitis C virus research (27 papers) and Liver Disease Diagnosis and Treatment (16 papers). John Fry collaborates with scholars based in United States, United Kingdom and France. John Fry's co-authors include Carol Brosgart, Shelly Xiong, Michael Wulfsohn, Patrick Marcellin, Seng Gee Lim, Zachary Goodman, Lennox J. Jeffers, William Sievert, Myron J. Tong and Ting‐Tsung Chang and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Annals of Internal Medicine.

In The Last Decade

John Fry

44 papers receiving 3.0k citations

Hit Papers

Adefovir Dipivoxil for the Treatment of Hepatitis B e Ant... 2003 2026 2010 2018 2003 2003 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B
    2003 1.0k citations Patrick Marcellin, Ting‐Tsung Chang et al. New England Journal of Medicine profile →
  2. Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B
    2003 749 citations Stephanos J. Hadziyannis, Nicolaos C. Tassopoulos et al. New England Journal of Medicine profile →

Peers

John Fry
F. Fabrizi Italy
Robert Perrillo United States
Mark Danta Australia
M. Chiaramonte Italy
Gabriella Verucchi Italy
Javier García‐Samaniego Spain
P Dentico Italy
Enea Spada Italy
Flavia Bortolotti Italy
Denis Ouzan France
F. Fabrizi Italy
John Fry
Citations per year, relative to John Fry John Fry (= 1×) peers F. Fabrizi

Countries citing papers authored by John Fry

Since Specialization
Citations

This map shows the geographic impact of John Fry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Fry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Fry more than expected).

Fields of papers citing papers by John Fry

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Fry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Fry. The network helps show where John Fry may publish in the future.

Co-authorship network of co-authors of John Fry

This figure shows the co-authorship network connecting the top 25 collaborators of John Fry. A scholar is included among the top collaborators of John Fry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Fry. John Fry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Peters, Marion G., Man‐Fung Yuen, Norah A. Terrault, et al.. (2023). Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes. Clinical Infectious Diseases. 78(4). 983–990. 5 indexed citations
2.
DeVincenzo, John P., Matthew W. McClure, Julian Symons, et al.. (2015). Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study. New England Journal of Medicine. 373(21). 2048–2058. 164 indexed citations
3.
Westland, C., Hao Yang, William E. Delaney, et al.. (2005). Activity of adefovir dipivoxil against all patterns of lamivudine‐resistant hepatitis B viruses in patients. Journal of Viral Hepatitis. 12(1). 67–73. 54 indexed citations
4.
Marcellin, Patrick, Ting‐Tsung Chang, Seng Gee Lim, et al.. (2003). Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B. New England Journal of Medicine. 348(9). 808–816. 1010 indexed citations breakdown →
5.
6.
Xiong, S., C. Westland, William E. Delaney, et al.. (2003). Resistance surveillance of HBEAG— chronic hepatitis B (CHB) patients treated for two years with adefovir dipivoxil (ADV). Journal of Hepatology. 38. 182–182. 35 indexed citations
7.
Neumann, Avidan U., Manuel Tsiang, Michael Wulfsohn, et al.. (2003). Predicting HBEAG loss by HBV DNA early kinetics and HBV genotype during treatment of HBEAG+ chronic hepatitis B (CHB) patients with adefovir dipivoxil (ADV). Journal of Hepatology. 38. 26–26. 3 indexed citations
8.
Shiffman, M., Jenny Heathcote, Robert G. Gish, et al.. (2003). Long-term safety beyond 48 weeks of adefovir dipivoxil (ADV) 10 Mg once daily for chronic hepatitis B (CHB): An integrated analysis of two phase III studies. Gastroenterology. 124(4). A709–A709. 1 indexed citations
9.
Westland, Christopher, Huiling Yang, William E. Delaney, et al.. (2003). Week 48 Resistance Surveillance in Two Phase 3 Clinical Studies of Adefovir Dipivoxil for Chronic Hepatitis B. Hepatology. 38(1). 96–103. 120 indexed citations
10.
Hadziyannis, Stephanos J., Nicolaos C. Tassopoulos, E. Jenny Heathcote, et al.. (2003). Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B. New England Journal of Medicine. 348(9). 800–807. 749 indexed citations breakdown →
11.
Marcellin, Patrick, Ting‐Tsung Chang, Seng Gee Lim, et al.. (2002). 48 weeks of adefovir dipivoxil (ADV) results in improvement in fibrosis and decreased progression of fibrosis in a double-blind, randomized, placebo-controlled study for the treatment of patients with HBeAg plus chronic hepatitis B.. Hepatology. 36(4). 3 indexed citations
12.
Chandra, Harish, Gilbert Raff, John Fry, et al.. (2002). Multifocal plaque instability correlates with elevated C-reactive protein. Journal of the American College of Cardiology. 39. 307–307.
13.
Yang, Huiling, Christopher Westland, William E. Delaney, et al.. (2002). Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology. 36(2). 464–473. 132 indexed citations
14.
Westland, Christopher, William E. Delaney, John Fry, et al.. (2002). Distribution and clinical response of HBV genotypes in phase III studies of adefovir dipivoxil. Journal of Hepatology. 36. 105–105. 4 indexed citations
15.
Marcellin, Patrick, Ting‐Tsung Chang, Seng Gee Lim, et al.. (2001). GS-98-437 a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for the treatment of patients with HBeAg+ chronic hepatitis B infection: 48 week results.. Hepatology. 34(4). 13 indexed citations
16.
Benhamou, Y., Vincent Thibault, Vincent Cálvez, et al.. (2001). Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. The Lancet. 358(9283). 718–723. 221 indexed citations
17.
Feinberg, Judith, Shelley Hurwitz, David K. C. Cooper, et al.. (1998). A Randomized, Double‐Blind Trial of Valaciclovir Prophylaxis for Cytomegalovirus Disease in Patients with Advanced Human Immunodeficiency Virus Infection. The Journal of Infectious Diseases. 177(1). 48–56. 93 indexed citations
18.
Fry, John. (1975). Long-surviving hypertensives--a 15-year follow-up.. PubMed. 25(156). 481–6. 1 indexed citations
19.
Fry, John. (1964). Peptic Ulcer: A profile. BMJ. 2(5412). 809–812. 102 indexed citations
20.
Fry, John, et al.. (1955). Peptic Ulcer in General Practice. BMJ. 2(4932). 169–172. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by F. Fabrizi Breakdown of academic impact, for papers by Robert Perrillo Breakdown of academic impact, for papers by Mark Danta Breakdown of academic impact, for papers by M. Chiaramonte Breakdown of academic impact, for papers by Gabriella Verucchi Breakdown of academic impact, for papers by Javier García‐Samaniego Breakdown of academic impact, for papers by P Dentico Breakdown of academic impact, for papers by Enea Spada Breakdown of academic impact, for papers by Flavia Bortolotti Breakdown of academic impact, for papers by Denis Ouzan
Rankless by CCL
2026